Last reviewed · How we verify
SHEUR (ELAGOLIX, ESTRADIOL AND NORETHINDRONE ACETATE AND ELAGOLIX)
SHEUR (generic name: ELAGOLIX, ESTRADIOL AND NORETHINDRONE ACETATE AND ELAGOLIX) is a drug developed by TEVA PHARM. It is currently FDA-approved.
At a glance
| Generic name | ELAGOLIX, ESTRADIOL AND NORETHINDRONE ACETATE AND ELAGOLIX |
|---|---|
| Sponsor | TEVA PHARM |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Real-world Experience of Elagolix With E2/NETA for the Treatment of Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF): an Observational Study (The REACH Study) (N/A)
- A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Pre (Phase 3)
- Phase 2a Proof Of Concept Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids (Phase 2)
- A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in P (Phase 3)
- A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in P (Phase 3)
- A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain (Phase 3)
- A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (Phase 2)
- A Study to Evaluate Safety and Efficacy of Elagolix Alone or Elagolix With Hormonal Add-Back in Subjects With Endometriosis With Associated Moderate to Severe Pain (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHEUR CI brief — competitive landscape report
- SHEUR updates RSS · CI watch RSS
- TEVA PHARM portfolio CI
Frequently asked questions about SHEUR
What is SHEUR?
SHEUR (ELAGOLIX, ESTRADIOL AND NORETHINDRONE ACETATE AND ELAGOLIX) is a pharmaceutical drug developed by TEVA PHARM.
Who makes SHEUR?
SHEUR is developed and marketed by TEVA PHARM (see full TEVA PHARM pipeline at /company/teva).
What is the generic name of SHEUR?
ELAGOLIX, ESTRADIOL AND NORETHINDRONE ACETATE AND ELAGOLIX is the generic (nonproprietary) name of SHEUR.
What development phase is SHEUR in?
SHEUR is FDA-approved (marketed).
Related
- Manufacturer: TEVA PHARM — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing